Product details

Describes how Eli Lilly and Co. tries to accelerate its new drug development process with the aid of "combinatorial chemistry"--a rapidly emerging and revolutionary approach to pre-clinical drug discovery. The product manager of a potential blockbuster migraine drug faces the decision of "racing" the drug to market or spending additional time to refine an already promising drug candidate. Focuses on: 1) the new drug development process with an emphasis on pre-clinical drug discovery; 2) radical innovations ("combinatorial chemistry") in the drug discovery process; 3) the managerial challenges of introducing such innovations into a large organization with multiple stakeholders; 4) the financial value of time-to-market; and 5) the changing competitive environment in the pharmaceutical industry.; Explores managerial issues that are typical in the adoption of new but very promising innovations that are likely to face resistance from stakeholders in an organization.